Juvenon Initiates Cardiovascular Disease Clinical Trial
CA, 6 May 2003
Energy Formula Designed to Improve Energy Levels and Reduce
Signs of Aging
Inc. today announced the initiation of a clinical trial to evaluate
the effect of Juvenon Energy Formula on cardiovascular disease
patients. The trial, funded by a grant from the National Institutes
of Health (NIH), is being conducted at the Whitaker Cardiovascular
Institute, a unit of Boston University School of Medicine. It is
designed to assess the effects of Juvenon Energy Formula on endothelial
function in elderly patients with coronary artery disease. Dysfunction
of the endothelial cells, the cells that line the blood vessels,
contributes to the progression of cardiovascular disease and is
recognized as an important surrogate for cardiovascular disease
Energy Formula has been shown in preclinical trials to reduce oxidative
damage to the mitochondria, thereby improving cellular function,"
said Joseph Vita, MD, Professor of Medicine, Boston University Medical
Center, and principal investigator. "Recent research indicates that
oxidative damage to the cells in the vascular system contributes
to the risk of heart disease. We hypothesize that an intervention
designed to improve cellular function, like Juvenon Energy Formula,
will have a beneficial effect on endothelial dysfunction in elderly
patients with cardiovascular disease."
Juvenon Energy Formula dietary supplement consists of two mitochondrial-activating
components that improve energy levels, reduce signs of aging in
revitalized cells and increase burning of fat for energy. This novel
supplement was developed at the University of California, Berkeley
by renowned scientist Bruce Ames, PhD, a winner of the National
Medal of Science and other international honors, and Tory Hagen,
PhD, a researcher at the Linus Pauling Institute at Oregon State
hope that the results from the trial will provide further validation
of Juvenon Energy Formula's role in promoting cellular health,"
said Dr. Bruce Ames, a professor of molecular and cell biology at
University of California, Berkeley and a researcher at Children's
Hospital Oakland Research Institute (CHORI). "The finding that this
supplement improves endothelial function would provide important
new information about the role of the mitochondria in aging and
40-person trial will determine the effect of Juvenon Energy Formula
on the endothelial cells that line the blood vessels. The trial
is designed to determine if an intervention to improve mitochondrial
function (Juvenon Energy Formula) will have a beneficial effect
on endothelial function. The study will test the blood vessels'
ability to respond to changes in blood flow by dilating (expanding).
Loss of normal dilator function reflects a loss of normal endothelial
function and is associated with an increased risk of heart attack
or stroke. The trial is designed as a double-blind, randomized,
placebo-controlled crossover study and will enroll patients from
55 to 95 years old with proven coronary artery disease.
mitochondria, the power plants of the cell, are the weak link in
aging. As we age, the efficiency of the mitochondria diminishes.
Evidence has been accumulating that deterioration of mitochondria
is an important cause of aging. The effects of agingfunctional
decline, degradation of physical appearance, and degenerative diseaseare
caused in large part by cumulative oxidative damage to mitochondria.
Energy Formula facilitates the entry of fuel (starches and
fatty acids) into mitochondria and stimulates production of natural
antioxidants that protect the mitochondria and the cell from age-associated
increases in tissue-damaging oxidants. It also restores the level
of cardiolipin, an important structural element in the mitochondrial
three articles in the 19 February 2002 issue of the Proceedings
of the National Academy of Sciences, Ames and his colleagues
reported results that showed that old laboratory rats, when given
the ingredients in Juvenon Energy Formula, functioned at levels
approaching those of much younger animals. The animals were more
active and energetic and performed better on memory tests. All mitochondrial
biochemical properties that were assayed were similar to those of
of the ingredients in the Juvenon Energy Formula has been individually
proven safe in clinical studies conducted over the past 30 years.
The product is currently being marketed as a dietary supplement.
Juvenon is committed to maintaining an active research program and
is presently conducting rigorous preclinical and clinical testing
of its Juvenon Energy Formula, despite the fact that dietary supplements
are not subject to FDA approval.
Inc. develops and sells products that promote cellular health and
help maintain vigor and vitality during aging. Juvenon has an exclusive,
worldwide license from the University of California, Berkeley for
the technology of Drs. Ames and Hagen, and has received its own
patents for certain cognitive effects and for increased energy and
stamina. Juvenon plans to develop and launch both dietary supplements
and nutritional products that focus on the mitochondria and the
mechanics of the cellular engine.